Risultati per: FDA approva un nuovo trattamento per l’emicrania

Mitiga il disagio se preso alle prime avvisaglie

Mitiga il disagio se preso alle prime avvisaglie

Saranno disponibili in Usa nei prossimi giorni

Cnn, l’ok a quelli aggiornati mRNA forse già questa settimana

This Viewpoint reviews regulations regarding FDA’s handing of confidential commercial information, explains how these regulations serve as a barrier to disclosure of information in the interest of public health, and suggests how information could be carefully shared to improve health outcomes and advance research.

The US Food and Drug Administration (FDA) recently announced new draft guidance that aims to increase the number of participants from underrepresented populations in clinical trials in the US and globally by requiring medical product sponsors to submit strategies, known as diversity action plans. Age, ethnicity, sex, and race are all factors that can contribute to clinical trial diversity, but sponsors should also consider types of diversity beyond those, such as geographic location, sexual orientation, or socioeconomic status, the FDA wrote.

The US Food and Drug Administration (FDA) recently approved donanemab, a monoclonal antibody to treat Alzheimer disease in its early stages. Marketed by Eli Lilly as Kisunla, the drug is the second to receive the FDA’s go-ahead for slowing Alzheimer disease, after lecanemab. Like lecanemab, donanemab is designed to clear amyloid plaque in people with mild cognitive impairment or mild dementia.

This Viewpoint discusses the recent US Supreme Court ruling allowing mifepristone—a drug used in medication abortion—to be widely available in the US, summarizes the history of challenges to the availability of mifepristone, and highlights reasons for concerns that remain after the Court’s current ruling.

This systematic review evaluates the representation of women in randomized clinical trials (RCTs) of US Food and Drug Administration (FDA)–supervised medical devices.

This systematic review examines the proportion and quality of postrecurrence treatment among patients in US Food and Drug Administration (FDA) registration trials of anticancer therapy in the neoadjuvant or adjuvant setting.

Con dose giornaliera in casa di polvere di arachidi

Corteccia cerebrale più sottile e permeabilità dell’intestino